Olssa (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil, the active ingredient in Olssa, is a angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension and may be used in adults requiring blood pressure control.

GNH USA supplies Olssa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olssa combines olmesartan medoxomil and amlodipine to address cardiovascular conditions that involve the renin‑angiotensin system and calcium‑channel mediated vascular tone. - Hypertension: helps lower systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertensive heart disease: assists in preventing left‑ventricular hypertrophy associated with long‑term high blood pressure. - Chronic kidney disease with hypertension: aids in slowing renal function decline by maintaining target blood pressure levels.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness, especially on standing. - Flushing: transient warmth or redness. - Fatigue: general feeling of tiredness. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of face, lips, tongue or throat. - Severe hypotension: symptomatic low blood pressure. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Acute kidney injury: sudden reduction in renal function. - Heart block or severe bradycardia: markedly slow heart rate. - Allergic rash or Stevens‑Johnson syndrome: severe skin reactions.

Before initiating Olssa, clinicians should evaluate patient history and monitor relevant parameters. - Renal function: assess baseline creatinine and eGFR, adjust if impaired. - Hepatic function: check liver enzymes in patients with liver disease. - Electrolytes: monitor potassium and sodium levels, especially if combined with diuretics. - Pregnancy: avoid use; drug is contraindicated in the second and third trimesters. - Concomitant antihypertensives: watch for additive blood‑pressure lowering effects. - Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.

Olssa may interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Aliskiren: concurrent use in diabetic patients can increase risk of renal impairment and hyperkalaemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can raise amlodipine levels.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response and affect renal function. - Lithium: increased lithium concentrations may occur. - Rifampicin: may reduce amlodipine exposure, lowering efficacy.